Concepedia

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

Arezoo Astanehe, Melanie Finkbeiner, Martin Krzywinski, Abbas Fotovati, Jaspreet Dhillon, Isabelle M. Berquin, Gordon B. Mills, Marco A. Marra, Sandra E. Dunn

Oncogene · 2012 · 53 citations · 52 references

DOIFull text

Open access

Concepts

References

52

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations

, , +14

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Charles L. Vogel · Journal of Clinical Oncology · 2002 · 3K citations

, , +17

The selectivity of protein kinase inhibitors: a further update

Jenny Bain, Lorna Plater, Matt Elliott et al. · Biochemical Journal · 2007 · 2.5K citations · Full text

, , +14

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Paul Carter, Leonard G. Presta, C Gorman et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations

, , +16

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.9K citations · Full text

, , +14